All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Saxenda weight loss pen: separating TikTok hype from clinical data

23

TikTok creator

2.8M viewsWatch on TikTok→

Quick answer

This video promotes Saxenda (liraglutide 3.0 mg), a GLP-1 receptor agonist approved for chronic weight management in adults with qualifying BMI, used here under physician supervision with concurrent dietary behavior modification. The creator's reported tolerability experience is possible but not representative of clinical trial populations, where gastrointestinal adverse effects including nausea affected the majority of participants. Appropriate candidate selection, slow dose titration, and ongoing clinical oversight are required for safe use.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @achibrabra actually say?

Honestly? Not much that can be fact-checked. The transcript captured in this video appears to be song lyrics, not medical commentary. The words attributed to @achibrabra are lines like "we ain't just up in the clouds" and "I just saw your light" — which are clearly audio from a background track, not the creator speaking directly about Saxenda or weight loss.

What we do have is the caption, which is where the real claims live. Translated from Thai, it reads roughly: "Love yourself, not painful at all even one day but costs money" — paired with the disclosure that she is "under doctor supervision and adjusting eating behavior alongside" the injections. The hashtags confirm this is about Saxenda (liraglutide), a GLP-1 receptor agonist.

So we're fact-checking a caption and a product experience, not a spoken medical claim. That context matters.

Does the science back this up?

The core implication — that Saxenda can support weight loss without pain when used under medical supervision alongside dietary changes — is broadly supported by the evidence. But "no pain" is where things get complicated.

Liraglutide 3.0 mg (Saxenda) was studied in the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine), which found participants lost an average of 8.4 kg over 56 weeks versus 2.8 kg on placebo. That's real, meaningful weight loss. The catch: 63.6% of participants reported nausea, and gastrointestinal side effects were the primary reason for discontinuation in about 9.9% of cases.

The "no pain" experience the creator describes is plausible for some people, especially if injection technique is good and doses are titrated slowly. But it is not the majority experience in clinical trials. Nausea, vomiting, and injection site reactions are common, not rare. The creator's experience is valid as personal testimony — it just shouldn't be read as typical.

What did they get wrong (or right)?

Credit where it's due: the caption disclosure is better than most GLP-1 content on TikTok. Saying she is "under doctor supervision" and "adjusting eating behavior alongside" the injection is exactly what responsible use of liraglutide looks like. Saxenda is not a standalone fix. A 2021 study by Rubino et al. in JAMA showed that patients who stopped semaglutide (a related GLP-1 drug) regained two-thirds of their lost weight within a year — reinforcing that behavioral change isn't optional, it's load-bearing.

What's missing, and what's problematic in its absence, is any acknowledgment of who Saxenda is approved for. The FDA indication is adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. The framing of "love yourself, not painful" could read as an invitation for anyone to try it, which is not accurate or safe guidance.

  • Right: Doctor supervision disclosed
  • Right: Behavioral eating changes mentioned as part of the process
  • Missing: Side effect acknowledgment
  • Missing: Eligibility criteria for appropriate use

What should you actually know?

Saxenda is a legitimate, FDA-approved medication for weight management. Liraglutide 3.0 mg is not a shortcut — it's a daily subcutaneous injection that works best when paired with caloric adjustment and physical activity, which the creator at least gestures toward.

The "no pain" framing deserves scrutiny. In the SCALE trial, nausea affected the majority of users. Some people do tolerate it well, particularly with slow dose escalation starting at 0.6 mg and increasing weekly. But tolerance varies substantially, and one person's painless experience doesn't generalize.

Cost is real, and the creator acknowledges it. Saxenda runs roughly $1,300-$1,400 per month out of pocket in the US without insurance coverage, which is a genuine barrier. Generic liraglutide is not currently available in the US market as of 2024.

If you're considering Saxenda or any GLP-1 medication for weight management, the starting point is a conversation with a licensed clinician who can assess your medical history, current medications, and whether the risk-benefit calculation makes sense for you specifically. Thyroid C-cell tumor risk — including a black box warning for medullary thyroid carcinoma — is a contraindication that a TikTok caption cannot screen for.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Saxenda weight loss pen: separating TikTok hype from clinical data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Saxenda weight loss pen: separating TikTok hype from clinical data is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim verdict

The useful answer behind this video

Claim being checked

This video promotes Saxenda (liraglutide 3.

FormBlends verdict

This video promotes Saxenda (liraglutide 3.0 mg), a GLP-1 receptor agonist approved for chronic weight management in adults with qualifying BMI, used here under physician supervision with concurrent dietary behavior modification. The creator's reported tolerability experience is possible but not representative of clinical trial populations, where gastrointestinal adverse effects including nausea affected the majority of participants. Appropriate candidate selection, slow dose titration, and ongoing clinical oversight are required for safe use.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • This video promotes Saxenda (liraglutide 3.0 mg), a GLP-1 receptor agonist approved for chronic weight management in adults with qualifying BMI, used here under physician supervision with concurrent dietary behavior modification. The creator's reported tolerability experience is possible but not representative of clinical trial populations, where gastrointestinal adverse effects including nausea affected the majority of participants. Appropriate candidate selection, slow dose titration, and ongoing clinical oversight are required for safe use.
  • In the SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM), liraglutide 3.0 mg produced average weight loss of 8.4 kg over 56 weeks, but 63.6% of users experienced nausea.
  • Saxenda carries a black box warning for medullary thyroid carcinoma risk and is contraindicated in patients with personal or family history of MTC or MEN 2 syndrome — something a TikTok caption cannot screen for.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • In the SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM), liraglutide 3.0 mg produced average weight loss of 8.4 kg over 56 weeks, but 63.6% of users experienced nausea.
  • Saxenda carries a black box warning for medullary thyroid carcinoma risk and is contraindicated in patients with personal or family history of MTC or MEN 2 syndrome — something a TikTok caption cannot screen for.
  • Rubino et al. (2021, JAMA) found that patients stopping a GLP-1 medication regained approximately two-thirds of lost weight within one year, confirming that behavioral change is not optional.
  • FDA approval for Saxenda requires a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. It is not indicated for general cosmetic weight loss.
  • Saxenda costs roughly $1,300-$1,400 per month out of pocket in the US as of 2024, with no generic liraglutide currently available on the US market.
  • The creator's positive tolerability experience is real but not representative. Slow dose titration starting at 0.6 mg weekly improves tolerance but does not eliminate side effects for most users.
  • The caption's disclosure of physician supervision and dietary behavior modification is clinically appropriate and more transparent than the majority of GLP-1 promotional content on social platforms.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

23 · TikTok creator

2.8M views on this video

‼️No sponsor‼️รักตัวเองไม่เจ็บเลยสักวันแต่เสียเงิน (อยู่ภายใต้การดูแลของหมอและปรับพฤติกรรมการกินควบคู่ไปด้วยนะคะ) #saxenda #ปากกาลดน้ำหนัก

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by 23, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.